Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade-Reference-Cited by-同舟云学术

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

Published:2019-04-01 Issue:4 Volume:5 Page:471
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Abida Wassim¹,Cheng Michael L.¹,Armenia Joshua²,Middha Sumit³,Autio Karen A.¹,Vargas Hebert Alberto⁴,Rathkopf Dana¹,Morris Michael J.¹,Danila Daniel C.¹,Slovin Susan F.¹,Carbone Emily¹,Barnett Ethan S.¹,Hullings Melanie¹,Hechtman Jaclyn F.⁵,Zehir Ahmet³,Shia Jinru⁵,Jonsson Philip²³,Stadler Zsofia K.¹,Srinivasan Preethi³,Laudone Vincent P.⁶,Reuter Victor⁵,Wolchok Jedd D.¹,Socci Nicholas D.³⁷,Taylor Barry S.²³,Berger Michael F.³⁵,Kantoff Philip W.¹,Sawyers Charles L.²,Schultz Nikolaus²³,Solit David B.¹²³,Gopalan Anuradha⁵,Scher Howard I.¹

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

2. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York

3. Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

4. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York

5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York

7. Bioinformatics Core, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/4/471/17459091/jamaoncology_abida_2018_oi_180103.pdf

Reference21 articles.

1. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer.;Beer;J Clin Oncol,2017

2. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.;Kwon;Lancet Oncol,2014

3. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer.;Topalian;N Engl J Med,2012

4. Early evidence of anti–PD-1 activity in enzalutamide-resistant prostate cancer.;Graff;Oncotarget,2016

5. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.;Le;Science,2017

Cited by 488 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors;Current Cancer Drug Targets;2024-11

2. Advances in and prospects of immunotherapy for prostate cancer;Cancer Letters;2024-10

3. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

4. Comprehensive scRNA-seq analysis to identify new markers of M2 macrophages for predicting the prognosis of prostate cancer;Annals of Medicine;2024-09-02

5. Complete Response to Pembrolizumab in a Patient with Castration-Resistant Prostate Cancer with Both BRCA Positivity and a High Frequency of Microsatellite Instability: A Case Report;Case Reports in Oncology;2024-08-05